Health Economics›Colorectal cancer›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Colorectal cancer · 65 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 41 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	MSI-H	R 286 955	14d	16.5 mo	77.5 mo	36	R 10 330 390 PFS proxy	3
Ipilimumab and Nivolumab Variant #01 Partial	MSI-H	R 78 615	42d	—	~18.2 mo	—	—	2
FOLFIRI and Cetuximab Variant #03	RAS	R 76 858	14d	8.9 mo	30.9 mo	20	R 1 537 158 PFS proxy	5
mFOLFOX6 and Cetuximab Variant #02	RAS	R 76 618	14d	8.2 mo	30.9 mo	18	R 1 379 118 PFS proxy	4
FOLFOX4 and Cetuximab Variant #01	RAS	R 53 661	14d	9.2 mo	22.1 mo	21	R 1 126 889 PFS proxy	3
FOLFIRI and Cetuximab (L-Leucovorin) Variant #01 Partial	RAS	R 53 467	14d	—	23.5 mo	—	—	1
CapeOx and Panitumumab Variant #01	RAS	R 40 265	21d	—	—	—	—	—
Atezolizumab monotherapy Variant #01	MSI-H	R 31 255	21d	~12.9 mo	~13.3 mo	~19	~R 593 838 PFS proxy · indirect	10
Capecitabine and Bevacizumab Variant #01	—	R 29 610	21d	9.2 mo	—	14	R 414 534 PFS proxy	4
FOLFOXIRI and Panitumumab Variant #01	RAS	R 28 021	14d	—	—	—	—	—
mFOLFOX6 and Panitumumab Variant #01	RAS	R 27 362	14d	12.8 mo	37.4 mo	28	R 766 126 PFS proxy	3
FOLFOX4 and Panitumumab Variant #01	RAS	R 27 318	14d	9.6 mo	23.8 mo	21	R 573 673 PFS proxy	2
mFOLFOXIRI and Cetuximab (L-Leucovorin) Variant #01 Partial	RAS	R 24 511	14d	—	—	—	—	—
FOLFOX4 and Bevacizumab Variant #01	—	R 21 146	14d	—	~12.9 mo	—	—	1
CapeOx and Bevacizumab Variant #01	—	R 16 696	21d	10.3 mo	—	15	R 250 437 PFS proxy	4
IFL and Bevacizumab Variant #01	—	R 16 148	21d	8.3 mo	19.5 mo	13	R 209 923 PFS proxy	3
CAPIRI-Bev Variant #01	—	R 16 013	21d	10.2 mo	—	15	R 240 199 PFS proxy	—
SOX and Bevacizumab Variant #01 Partial	—	R 15 709	21d	11.7 mo	—	17	R 267 060 PFS proxy	1
IRIS and Bevacizumab Variant #01 Partial	—	R 15 273	21d	14.0 mo	—	21	R 320 743 PFS proxy	1
FOLFIRINOX and Bevacizumab Variant #01	—	R 12 910	14d	11.5 mo	—	26	R 335 666 PFS proxy	1
FOLFIRI and Bevacizumab Variant #01	—	R 12 367	14d	7.6 mo	32.4 mo	17	R 210 247 PFS proxy	4
FOLFIRI and Bevacizumab Variant #01	RAS	R 12 367	14d	7.6 mo	32.4 mo	17	R 210 247 PFS proxy	4
FOLFIRI and Bevacizumab Variant #01	MSI-H	R 12 367	14d	7.6 mo	32.4 mo	17	R 210 247 PFS proxy	4
mFOLFOX6-B Variant #01	—	R 12 127	14d	10.1 mo	29.0 mo	22	R 266 798 PFS proxy	10
mFOLFOX6-B Variant #01	RAS	R 12 127	14d	10.1 mo	29.0 mo	22	R 266 798 PFS proxy	10
mFOLFOX6-B Variant #01	MSI-H	R 12 127	14d	10.1 mo	29.0 mo	22	R 266 798 PFS proxy	10
FOLFIRINOX and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 11 953	14d	12.1 mo	31.0 mo	27	R 322 733 PFS proxy	2
FULV and Bevacizumab Variant #02	—	R 11 648	14d	—	—	—	—	—
FOLFIRI and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 11 410	14d	10.9 mo	25.8 mo	24	R 273 847 PFS proxy	3
mFOLFOX6-B (L-Leucovorin) Variant #01 Partial	—	R 11 170	14d	11.2 mo	—	25	R 279 250 PFS proxy	2
FULV and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 10 256	14d	9.4 mo	—	21	R 215 377 PFS proxy	1
FUFOX Variant #01	—	R 7 211	35d	8.0 mo	—	7	R 50 479 PFS proxy	1
FOLFOX2 Variant #01	—	R 4 153	14d	—	18.7 mo	—	—	1
FOLFIRINOX Variant #03	RAS	R 3 740	14d	—	22.6 mo	—	—	1
FOLFIRINOX Variant #03	—	R 3 740	14d	—	22.6 mo	—	—	1
FOLFOX 7/sLV5FU2 Variant #01	—	R 3 482	14d	—	—	—	—	—
mFOLFOX7 Variant #01	—	R 2 857	14d	—	—	—	—	—
FOLFIRI Variant #05	MSI-H	R 2 826	14d	8.4 mo	19.5 mo	19	R 53 701 PFS proxy	13
FOLFIRI Variant #05	RAS	R 2 826	14d	8.4 mo	19.5 mo	19	R 53 701 PFS proxy	13
FOLFIRI Variant #05	—	R 2 826	14d	8.4 mo	19.5 mo	19	R 53 701 PFS proxy	13
mFOLFOX6 Variant #02	MSI-H	R 2 466	14d	9.5 mo	23.3 mo	21	R 51 796 PFS proxy	6
mFOLFOX6 Variant #02	—	R 2 466	14d	9.5 mo	23.3 mo	21	R 51 796 PFS proxy	6
CapeOx Variant #01	—	R 2 384	21d	6.9 mo	19.9 mo	11	R 26 226 PFS proxy	2
Capecitabine monotherapy Variant #17	—	R 2 219	21d	5.7 mo	—	9	R 19 974 PFS proxy	3
IROX Variant #01	—	R 2 196	21d	—	~13.4 mo	—	—	1
FOLFOX4 Variant #01	RAS	R 2 064	14d	8.2 mo	19.4 mo	18	R 37 145 PFS proxy	6
FOLFOX4 Variant #01	—	R 2 064	14d	8.2 mo	19.4 mo	18	R 37 145 PFS proxy	6
mFOLFOX7 (L-Leucovorin) Variant #01 Partial	—	R 1 900	14d	—	—	—	—	—
FOLFIRI (L-Leucovorin) Variant #01 Partial	—	R 1 869	14d	8.4 mo	17.0 mo	19	R 35 515 PFS proxy	2
FOLFOX6 Variant #01	—	R 1 750	14d	6.7 mo	—	15	R 26 250 PFS proxy	—
OXAFAFU Variant #01	—	R 1 629	14d	—	18.9 mo	—	—	—
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 1 629	14d	—	23.3 mo	—	—	1
FULV Variant #01	—	R 1 466	35d	6.2 mo	13.1 mo	6	R 8 795 PFS proxy	6
IFL Variant #01	—	R 1 413	21d	4.2 mo	15.4 mo	7	R 9 891 PFS proxy	2
Nordic FLOX Variant #01	—	R 1 339	14d	—	—	—	—	—
FUOX Variant #01	—	R 1 223	14d	—	~10.6 mo	—	—	—
FOLFOX4 (L-Leucovorin) Variant #01 Partial	—	R 1 106	14d	6.7 mo	—	15	R 16 597 PFS proxy	2
SOX Variant #01 Partial	—	R 1 075	21d	8.5 mo	—	13	R 13 978 PFS proxy	1
Fluorouracil monotherapy Variant #16	—	R 858	42d	—	10.0 mo	—	—	—
FULV (L-Leucovorin) Variant #06 Partial	—	R 825	14d	—	~6.1 mo	—	—	1
FUIRI Variant #01	—	R 822	7d	—	—	—	—	—
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	—	~10.9 mo	—	—	4
CAPIRI N/A - secondary systemic drug	—	R 1	21d	5.9 mo	—	9	R 12 PFS proxy	1
FOLFOX 7/sLV5FU2 (L-Leucovorin) Partial	—	—	—	—	—	—	—	—
S-1 monotherapy Variant #01 Partial	—	—	21d	~1.7 mo	~10.5 mo	~3	—	13

65 of 65 regimens shown